To appraise the clinical and cost-effectiveness of Nivolumab in combination with relatlimab within its marketing authorisation for melanoma
Status In progress
Process STA 2018
ID number 1612


Key events during the development of the guidance:

Date Update
08 May 2019 In progress, Referred 17 October 2018

For further information on how we develop guidance, please see our page about NICE technology appraisal guidance